• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

维多珠单抗治疗两种不同的抗肿瘤坏死因子α难治性袋状结肠炎的有效性：一例报告。

Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report.

作者信息

Cakir Ozlem Ozer

机构信息

Department of Gastroenterology and Hepatology, Alanya Alaaddin Keykubat University, School of Medicine, Antalya 07425, Turkey.

出版信息

World J Clin Cases. 2019 Aug 26;7(16):2316-2321. doi: 10.12998/wjcc.v7.i16.2316.

DOI:10.12998/wjcc.v7.i16.2316
PMID:31531325
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6718792/
Abstract

BACKGROUND

Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. We aimed to show the effect of vedolizumab on treatment of the patient with refractory pouchitis.

CASE SUMMARY

A 32-year-old male with pancolonic ulcerative colitis since the age of 25 with primary failure of infliximab and mesalamine and intolerance of azathioprine, underwent a total proctocolectomy with ileal pouch-anal anastomosis in 2012. He developed chronic diarrhea in 2014, which was watery, 30 per day and accompanied with blood and mucus affecting his quality of life.

CONCLUSION

Vedolizumab is safe and effective in the management of anti-tumor necrosis factor alpha refractory pouchitis.

摘要

背景

难治性袋炎是袋状结构功能衰竭的常见原因，可能需要手术切除袋状结构或永久性造口。我们旨在展示维多珠单抗对难治性袋炎患者的治疗效果。

病例摘要

一名32岁男性，自25岁起患有全结肠溃疡性结肠炎，英夫利昔单抗和美沙拉嗪初治失败，且对硫唑嘌呤不耐受，于2012年接受了全直肠结肠切除术及回肠袋肛管吻合术。2014年他出现慢性腹泻，呈水样便，每天30次，并伴有血便和黏液便，影响其生活质量。

结论

维多珠单抗在治疗抗肿瘤坏死因子α难治性袋炎方面安全有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b16/6718792/6e176202b75e/WJCC-7-2316-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b16/6718792/eee824c1cb0e/WJCC-7-2316-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b16/6718792/6e176202b75e/WJCC-7-2316-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b16/6718792/eee824c1cb0e/WJCC-7-2316-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b16/6718792/6e176202b75e/WJCC-7-2316-g002.jpg

相似文献

1
Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report.维多珠单抗治疗两种不同的抗肿瘤坏死因子α难治性袋状结肠炎的有效性：一例报告。
World J Clin Cases. 2019 Aug 26;7(16):2316-2321. doi: 10.12998/wjcc.v7.i16.2316.
2
Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.慢性抗生素难治性 pouchitis 中生物治疗的结果：回顾性单中心经验。
United European Gastroenterol J. 2019 Nov;7(9):1215-1225. doi: 10.1177/2050640619871797. Epub 2019 Aug 20.
3
Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.柳氮磺胺吡啶预防溃疡性结肠炎行结直肠切除回肠储袋肛管吻合术后储袋炎
Dig Dis Sci. 2017 Apr;62(4):1016-1024. doi: 10.1007/s10620-017-4454-9. Epub 2017 Jan 21.
4
[A case of refractory pouchitis following surgery for ulcerative colitis successfully treated with adalimumab].[1例溃疡性结肠炎手术后难治性袋炎经阿达木单抗成功治疗的病例]
Nihon Shokakibyo Gakkai Zasshi. 2019;116(9):732-738. doi: 10.11405/nisshoshi.116.732.
5
Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis.系统评价与荟萃分析：抗 TNF 治疗在回肠贮袋肛门吻合术后溃疡性结肠炎切除术后难治性贮袋炎和类似克罗恩病的贮袋并发症中的应用。
Inflamm Bowel Dis. 2018 Jan 18;24(2):261-268. doi: 10.1093/ibd/izx049.
6
Pouchitis after ileal pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, risk factors, and incidence.溃疡性结肠炎回肠贮袋-肛门吻合术后 pouchitis 的诊断、处理、危险因素和发生率。
Dig Endosc. 2017 Jan;29(1):26-34. doi: 10.1111/den.12744. Epub 2016 Nov 7.
7
Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis.抗肿瘤坏死因子药物的暴露会增加溃疡性结肠炎患者直肠结肠切除术后 pouchitis 的发生率。
Dis Colon Rectum. 2019 Nov;62(11):1344-1351. doi: 10.1097/DCR.0000000000001467.
8
Collagenous pouchitis.胶原性袋炎
Dig Liver Dis. 2006 Sep;38(9):704-9. doi: 10.1016/j.dld.2006.05.022. Epub 2006 Jun 27.
9
Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases.回肠肛管袋状吻合术患者特定巨细胞病毒感染误诊为难治性特发性慢性袋炎：2例报告
Dis Colon Rectum. 1999 Jan;42(1):117-20. doi: 10.1007/BF02235196.
10
Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis.英夫利昔单抗治疗溃疡性结肠炎回肠肛管袋状吻合术后并发瘘管的难治性袋炎
Aliment Pharmacol Ther. 2003 May 15;17(10):1263-71. doi: 10.1046/j.1365-2036.2003.01535.x.

引用本文的文献

1
Key Focus Areas in Pouchitis Therapeutic Status: A Narrative Review. pouchitis 治疗现状的重点关注领域：叙述性综述。
Iran J Med Sci. 2024 Aug 1;49(8):472-486. doi: 10.30476/ijms.2024.100782.3326. eCollection 2024 Aug.
2
α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.在慢性难治性袋炎患者中，维多珠单抗可阻断T细胞通过α4β7整合素依赖性方式与黏膜地址素细胞黏附分子-1（MAdCAM-1）的黏附。
Therap Adv Gastroenterol. 2021 Nov 24;14:17562848211054707. doi: 10.1177/17562848211054707. eCollection 2021.

本文引用的文献

1
Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort.维多利珠单抗治疗回肠贮袋炎的疗效：来自美国多中心队列研究的结果。
Inflamm Bowel Dis. 2019 Aug 20;25(9):1569-1576. doi: 10.1093/ibd/izz030.
2
Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab.维多珠单抗成功治疗难治性慢性袋炎和自身免疫性溶血性贫血
GE Port J Gastroenterol. 2018 Nov;25(6):340-341. doi: 10.1159/000486803. Epub 2018 Feb 14.
3
Vedolizumab in the treatment of Crohn's disease of the pouch.
维多珠单抗治疗储袋型克罗恩病
Gastroenterol Rep (Oxf). 2018 Aug;6(3):184-188. doi: 10.1093/gastro/goy014. Epub 2018 Jun 22.
4
Use of vedolizumab in a patient with chronic and refractory pouchitis.
Ann Gastroenterol. 2018 May-Jun;31(3):379. doi: 10.20524/aog.2018.0243. Epub 2018 Mar 3.
5
Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.维得利珠单抗治疗慢性、抗生素依赖或难治性 pouchitis。
Aliment Pharmacol Ther. 2018 Mar;47(5):581-587. doi: 10.1111/apt.14479. Epub 2017 Dec 19.
6
Successful Treatment With Vedolizumab in a Patient With Chronic Refractory Pouchitis and Primary Sclerosing Cholangitis.维多珠单抗成功治疗一例慢性难治性袋炎合并原发性硬化性胆管炎患者
J Crohns Colitis. 2017 Dec 4;11(12):1507-1508. doi: 10.1093/ecco-jcc/jjx090.
7
Successful treatment of chronic refractory pouchitis with vedolizumab.维多珠单抗成功治疗慢性难治性袋炎。
Int J Colorectal Dis. 2017 Oct;32(10):1517-1518. doi: 10.1007/s00384-017-2854-0. Epub 2017 Jul 11.
8
Successful treatment of pouchitis with Vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis.溃疡性结肠炎患者行直肠结肠切除术后，维多珠单抗成功治疗袋炎，但粪菌移植（FMT）无效。
Int J Colorectal Dis. 2017 Apr;32(4):597-598. doi: 10.1007/s00384-017-2761-4. Epub 2017 Jan 17.
9
Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis.维多珠单抗治疗对抗生素和抗肿瘤坏死因子难治性袋状结肠炎患者的疗效
Inflamm Bowel Dis. 2017 Jan;23(1):E5-E6. doi: 10.1097/MIB.0000000000000992.
10
Use of Biologics in Pouchitis: A Systematic Review.生物制剂在袋炎中的应用：一项系统评价
J Clin Gastroenterol. 2015 Sep;49(8):647-54. doi: 10.1097/MCG.0000000000000367.